SEC Filing Summary for Agios Pharmaceuticals, Inc.

This filing details transactions by Brian Goff, Chief Executive Officer and Director of Agios Pharmaceuticals, Inc. On June 18, 2026, Goff acquired 39,000 restricted stock units (RSUs) and 39,000 performance share units (PSUs) under a direct ownership nature. Both transactions had a price per share of $0.00. The RSUs and PSUs are contingent rights to receive one share of the company's common stock each. The PSUs vest upon achievement of specified clinical and research milestones, with one milestone determined to be met as of June 18, 2026. The shares related to this milestone will vest on December 31, 2027, subject to continued service. Following these transactions, Goff holds 39,000 shares of common stock underlying the RSUs and 39,000 shares underlying the PSUs.